110 related articles for article (PubMed ID: 11424441)
1. [Evaluation of serum pepsinogen test for screening of gastric cancer].
Nishizawa M; Shiga T; Hayashi M
Nihon Rinsho; 2001 Apr; 59 Suppl 4():538-42. PubMed ID: 11424441
[No Abstract] [Full Text] [Related]
2. Screening for gastric cancer in Western countries.
Lansdorp-Vogelaar I; Kuipers EJ
Gut; 2016 Apr; 65(4):543-4. PubMed ID: 26611232
[No Abstract] [Full Text] [Related]
3. Gut to lung.
Knapp S
Gut; 2016 Apr; 65(4):544-5. PubMed ID: 26531717
[No Abstract] [Full Text] [Related]
4. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography.
Ohata H; Oka M; Yanaoka K; Shimizu Y; Mukoubayashi C; Mugitani K; Iwane M; Nakamura H; Tamai H; Arii K; Nakata H; Yoshimura N; Takeshita T; Miki K; Mohara O; Ichinose M
Cancer Sci; 2005 Oct; 96(10):713-20. PubMed ID: 16232204
[TBL] [Abstract][Full Text] [Related]
5. Serum pepsinogen and gastric cancer screening.
Mukoubayashi C; Yanaoka K; Ohata H; Arii K; Tamai H; Oka M; Ichinose M
Intern Med; 2007; 46(6):261-6. PubMed ID: 17379991
[TBL] [Abstract][Full Text] [Related]
6. [Current situation and future of gastric cancer screening examinations: from the viewpoint of gastric X-ray screening].
Kitagawa M
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Jun; 61(6):881-6. PubMed ID: 15995621
[TBL] [Abstract][Full Text] [Related]
7. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males.
Yanaoka K; Oka M; Mukoubayashi C; Yoshimura N; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Ohata H; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):838-45. PubMed ID: 18398025
[TBL] [Abstract][Full Text] [Related]
8. Western long-term accuracy of serum pepsinogen-based gastric cancer screening.
Castro C; Dinis-Ribeiro M; Rodrigues ANG; Calheiros T; Santos J; Pereira P; Ramos M; Cunha H; Andrade M; Costa A; Sá L; Antunes L; Bento MJ; Lomba-Viana R
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):274-277. PubMed ID: 29215432
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of guideline for stomach cancer mass screening].
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1183-97. PubMed ID: 16955959
[No Abstract] [Full Text] [Related]
10. Validity of serum pepsinogen levels and quininium resin test combined for gastric cancer screening.
Kim JR; Lee K; Jung WT; Lee OJ; Kim TH; Kim HJ; Lee JS; Passaro DJ
Cancer Detect Prev; 2005; 29(6):570-5. PubMed ID: 16289505
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
Gong YH; Sun LP; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
[TBL] [Abstract][Full Text] [Related]
12. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.
Sugiu K; Kamada T; Ito M; Kaya S; Tanaka A; Kusunoki H; Hata J; Haruma K
Dig Liver Dis; 2006 May; 38(5):303-7. PubMed ID: 16549394
[TBL] [Abstract][Full Text] [Related]
13. [Serum pepsinogen I/II ratio test].
Miki K
Nihon Rinsho; 2003 Jan; 61(1):92-5. PubMed ID: 12607323
[TBL] [Abstract][Full Text] [Related]
14. Challenges in evaluation of screening for gastric cancer among men based on nonrandomized design.
Vohlonen I; Härkönen M; Malila N; Pukkala E; Sipponen P; Koistinen V; Hakama M
Acta Oncol; 2017 Jul; 56(7):917-922. PubMed ID: 28514928
[TBL] [Abstract][Full Text] [Related]
15. Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach.
Parthasarathy G; Maroju NK; Kate V; Ananthakrishnan N; Sridhar MG
Trop Gastroenterol; 2007; 28(4):166-70. PubMed ID: 18416347
[TBL] [Abstract][Full Text] [Related]
16. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica.
Con SA; Con-Wong R; Con-Chin GR; Con-Chin VG; Takeuchi H; Valerín AL; Echandi G; Mena F; Brenes F; Yasuda N; Araki K; Sugiura T
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2631-6. PubMed ID: 18086767
[TBL] [Abstract][Full Text] [Related]
17. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study.
Mizuno S; Kobayashi M; Tomita S; Miki I; Masuda A; Onoyama M; Habu Y; Inokuchi H; Watanabe Y
Gastric Cancer; 2009; 12(3):158-63. PubMed ID: 19890696
[TBL] [Abstract][Full Text] [Related]
18. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
19. Pathology of gastric intestinal metaplasia: clinical implications.
Correa P; Piazuelo MB; Wilson KT
Am J Gastroenterol; 2010 Mar; 105(3):493-8. PubMed ID: 20203636
[No Abstract] [Full Text] [Related]
20. [Evaluation on a gastric mass survey-comparison with gastric mass screening using photofluorography and that using serum pepsinogen].
Tomooka Y
Nihon Koshu Eisei Zasshi; 1996 Feb; 43(2):118-25. PubMed ID: 8901216
[No Abstract] [Full Text] [Related]
[Next] [New Search]
